Select a service area View all services (A-Z listing)
Use one of the following options to find your doctor at Cabrini

Looking for a physiotherapist or other professional? See Allied Health

Cancer Trials at Cabrini

The Oncology Clinical Trials Program enables patients to access a wide spectrum of newly advanced treatments including immunotherapeutic drugs and targeted therapies for a range of solid and haematological malignancies.


Established in 2003 and led by Associate Professor Gary Richardson OAM, the Department aims to provide compassionate, state-of-the-art care for cancer patients and continued advancements in the prevention, diagnosis, treatment and cure of cancer via a combination of research, education and clinical practice.

Phase I

A Phase 1b/2 Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB-3111 with Obinutuzumab in Subjects with B-cell Lymphoid Malignancies

Registered Trial Number - BGB-311_GA101_Study_001

Download our Fast Fact document >

A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects with Advanced Tumours

Registered Trial Number - BGB-A317

Download our Fast Fact document >

A Phase 1/1b, Open-Label, Multicentre, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

Registered Trial Number - CPI-444-001

Download our Fast Fact document >


Phase IIIb, Randomized, Study of Multiple Administration Regimes for Nivolumab Plus Ipilimumab in Subjects with Previously Untreated Unresectable or Metastatic Melanoma

Registered Trial Number - CA209742

Download our Fast Fact document >


A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin in First Line Therapy in unresectable Pleural Mesothelioma

Registered Trial Number - CA209743

Download our Fast Fact document >

Haematological / Blood cancers

A Phase II, international, multicentre, randomized, open-label, parallel group study to evaluate the efficacy and safety of CC-486 (oral Azacitidine) alone and in combination with Durvalumab (MEDI4736) in subjects with Myelodysplastic syndromes who fail to achieve an objective response to treatment with Azacitidine for injection or Decitabine

Registered Trial Number - CC-486-MDS-006

Download our Fast Fact document >

A Phase 3, Multicentre, Randomized, Doubleblind Study to Compare the Efficacy and Safety of Oral Azacitidine plus Best Supportive Care versus Placebo plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia due to IPSS Lower-Risk Myelodysplastic Syndromes

Registered Trial Number - AZA-MDS-003

Download our Fast Fact document >


Circulating Tumour DNA Analysis Informing Adjuvant Chemo in Stage II Colon Cancer (DYNAMIC)

Registered Trial Number - WEHI - ctDNA - 04

Download our Fast Fact document >

A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128 + MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MPL0128 in Women with Advanced, Recurrent, or Persistent Endometrial Cancer

Registered Trial Number - C31004

Download our Fast Fact document >

Kidney / Renal

Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab plus Ipilimumab in Participants with Renal Cell Carcinoma.
The purpose of this study is to evaluate safety and efficacy of different administration regimens of nivolumab plus ipilimumab in subjects with renal cell carcinoma.

Registered Trial Number - CA209800

Download our Fast Fact document >

There are no results to your search.

The keyword you entered is too short. Please use at least three characters.